Cart
sales@molnova.com
NNGH
CAS No. 161314-17-6
NNGH( —— )
Catalog No. M33755 CAS No. 161314-17-6
NNGH is a matrix metalloproteinase 3 (MMP-3) inhibitor with anticancer activity that counteracts the inhibitory effects of E2 and DHT on RANKL membrane binding.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 226 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameNNGH
-
NoteResearch use only, not for human use.
-
Brief DescriptionNNGH is a matrix metalloproteinase 3 (MMP-3) inhibitor with anticancer activity that counteracts the inhibitory effects of E2 and DHT on RANKL membrane binding.
-
DescriptionNNGH is a stromelysin-1 (MMP-3) inhibitor. MMP-3 is both a direct transcriptional target and a necessary contributor of the Wnt/β-catenin signaling pathway. Matrix metalloproteinases (MMPs) play a well-defined role in later stages of tumor progression.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayMetabolic Enzyme/Protease
-
TargetMMP
-
RecptorMMP
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number161314-17-6
-
Formula Weight316.37
-
Molecular FormulaC13H20N2O5S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=C(NO)CN(CC(C)C)S(=O)(=O)C1=CC=C(OC)C=C1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Laurence Blavier, et al. Stromelysin-1 (MMP-3) is a target and a regulator of Wnt1-induced epithelial-mesenchymal transition (EMT). Cancer Biol Ther. 2010 Jul 15;10(2):198-208.?
molnova catalog
related products
-
Tanomastat
Tanomastat (BAY 129566) is a potent,orally available, non-peptidic inhibitor of MMP-2, MMP-3 and MMP-9 with 11, 143 and 301 nM, respectively.
-
Marimastat
A broad spectrum MMP inhibitor for MMP9/1/2/14/7 with IC50 of 3/5/6/9/13 nM, respectively.
-
Colistimethate Sodiu...
Colistimethate Sodium is used for the treatment of serious infections due to selected aerobic Gram-negative pathogens in patients with limited treatment options.
